Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Chronic Renal Failure

  Free Subscription


Articles published in Curr Opin Nephrol Hypertens

Retrieve available abstracts of 114 articles:
HTML format



Single Articles


    June 2021
  1. SAEED F, Shah AY, Allen RJ, Epstein RM, et al
    Communication principles and practices for making shared decisions about renal replacement therapy: a review of the literature.
    Curr Opin Nephrol Hypertens. 2021 Jun 18. pii: 00041552-900000000-98977.
    PubMed     Abstract available


    May 2021
  2. COHEN-BUCAY A, Francis JM, Gordon CE
    Progress in hepatitis C virus management in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021 May 28. pii: 00041552-900000000-98979.
    PubMed     Abstract available


  3. PARVATHAREDDY VP, Ella KM, Shah M, Navaneethan SD, et al
    Treatment options for managing obesity in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021 May 25. pii: 00041552-900000000-98980.
    PubMed     Abstract available


  4. SMEIJER JD, Kohan DE, Webb DJ, Dhaun N, et al
    Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021 May 10. pii: 00041552-900000000-98984.
    PubMed     Abstract available


  5. CHALUPSKY M, Goodson DA, Gamboa JL, Roshanravan B, et al
    New insights into muscle function in chronic kidney disease and metabolic acidosis.
    Curr Opin Nephrol Hypertens. 2021;30:369-376.
    PubMed     Abstract available


  6. VLASSCHAERT C, Sidhu B, Silver SA
    Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes.
    Curr Opin Nephrol Hypertens. 2021;30:361-368.
    PubMed     Abstract available


  7. ARIF H, Yadav A
    Approach to stable angina in patients with advanced chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021;30:339-345.
    PubMed     Abstract available


    April 2021
  8. DAMRATH JG, Creecy A, Wallace JM, Moe SM, et al
    The impact of advanced glycation end products on bone properties in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021 Apr 28. pii: 00041552-900000000-98985.
    PubMed     Abstract available


    January 2021
  9. CLARK-CUTAIA MN, Rivera E, Iroegbu C, Squires A, et al
    Disparities in chronic kidney disease-the state of the evidence.
    Curr Opin Nephrol Hypertens. 2021 Jan 13. pii: 00041552-900000000-99003.
    PubMed     Abstract available


  10. KOURI AM, Rheault MN
    Cardiovascular disease in children with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021 Jan 13. pii: 00041552-900000000-99002.
    PubMed     Abstract available


  11. PREMACHANDRA KH, Day RO, Roberts DM
    Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
    Curr Opin Nephrol Hypertens. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    December 2020
  12. NAIR D, Malhotra S, Lupu D, Harbert G, et al
    Challenges in communication, prognostication and dialysis decision-making in the COVID-19 pandemic: implications for interdisciplinary care during crisis settings.
    Curr Opin Nephrol Hypertens. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  13. SOOMRO QH, Charytan DM
    Cardiovascular autonomic nervous system dysfunction in chronic kidney disease and end-stage kidney disease: disruption of the complementary forces.
    Curr Opin Nephrol Hypertens. 2020;Publish Ahead of Print.
    PubMed     Abstract available


    November 2020
  14. ZARANTONELLO D, Rhee CM, Kalantar-Zadeh K, Brunori G, et al
    Novel conservative management of chronic kidney disease via dialysis-free interventions.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000670.
    PubMed     Abstract available


  15. TANTISATTAMO E, Kalantar-Zadeh K
    Novel therapeutic approaches in chronic kidney disease, uremia and kidney transplantation: past, present and future.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000677.
    PubMed    


  16. STREJA E, Norris KC, Budoff MJ, Hashemi L, et al
    The quest for cardiovascular disease risk prediction models in patients with nondialysis chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000672.
    PubMed     Abstract available


  17. FERREY AJ, Hanna R, Reddy UG, Tantisattamo E, et al
    Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000671.
    PubMed     Abstract available


  18. TANTISATTAMO E, Leventhal JR, Mathew JM, Gallon L, et al
    Chimerism and tolerance: past, present and future strategies to prolong renal allograft survival.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000666.
    PubMed     Abstract available


  19. HANNA RM, Ferrey A, Rhee CM, Sam R, et al
    Building a hemodiafiltration system from readily available components for continuous renal replacement therapy under disasters and pandemics: preparing for an acute kidney injury surge during COVID-19.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000658.
    PubMed     Abstract available


  20. MUREA M
    Precision medicine approach to dialysis including incremental and decremental dialysis regimens.
    Curr Opin Nephrol Hypertens. 2020 Nov 6. doi: 10.1097/MNH.0000000000000667.
    PubMed     Abstract available


  21. SUMIDA K, Lau WL, Kovesdy CP, Kalantar-Zadeh K, et al
    Microbiome modulation as a novel therapeutic approach in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Nov 2. doi: 10.1097/MNH.0000000000000661.
    PubMed     Abstract available


  22. JUDGE PK, Haynes R
    taleNeprilysin and Neprilysin inhibition in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Nov 2. doi: 10.1097/MNH.0000000000000659.
    PubMed     Abstract available


  23. HUR L, McIntyre CW
    Current and novel imaging techniques to evaluate myocardial dysfunction during hemodialysis.
    Curr Opin Nephrol Hypertens. 2020;29:555-563.
    PubMed     Abstract available


  24. CHUKWU CA, Middleton R, Kalra PA
    Recurrent glomerulonephritis after renal transplantation.
    Curr Opin Nephrol Hypertens. 2020;29:636-644.
    PubMed     Abstract available


  25. VIRAMONTES-HORNER D, Taal MW
    Nutritional status assessment: a neglected biomarker in persons with end-stage kidney disease.
    Curr Opin Nephrol Hypertens. 2020;29:547-554.
    PubMed     Abstract available


    September 2020
  26. BOJIC M, Watschinger C, Reiter T, Watschinger B, et al
    Waiting times in renal transplant candidates with a history of malignancy: time for a change?
    Curr Opin Nephrol Hypertens. 2020 Sep 15. doi: 10.1097/MNH.0000000000000652.
    PubMed     Abstract available


  27. ROY PJ, Weltman M, Dember LM, Liebschutz J, et al
    Pain management in patients with chronic kidney disease and end-stage kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Sep 15. doi: 10.1097/MNH.0000000000000646.
    PubMed     Abstract available


  28. LEVESON J, Oates TM
    Exome sequencing as a diagnostic tool in chronic kidney disease: ready for clinical application?
    Curr Opin Nephrol Hypertens. 2020 Sep 2. doi: 10.1097/MNH.0000000000000639.
    PubMed     Abstract available


  29. DE RUITER A, Bello A, Braam B
    Fluid management in chronic kidney disease: what is too much, what is the distribution, and how to manage fluid overload in patients with chronic kidney disease?
    Curr Opin Nephrol Hypertens. 2020 Sep 2. doi: 10.1097/MNH.0000000000000640.
    PubMed     Abstract available


  30. MAVRAKANAS TA, Charytan DM, Winkelmayer WC
    Direct oral anticoagulants in chronic kidney disease: an update.
    Curr Opin Nephrol Hypertens. 2020;29:489-496.
    PubMed     Abstract available


    July 2020
  31. WILKINSON TJ, McAdams-DeMarco M, Bennett PN, Wilund K, et al
    Advances in exercise therapy in predialysis chronic kidney disease, hemodialysis, peritoneal dialysis, and kidney transplantation.
    Curr Opin Nephrol Hypertens. 2020 Jul 20. doi: 10.1097/MNH.0000000000000627.
    PubMed     Abstract available


  32. ALI S, Ajmal MS, Navaneethan SD
    Management of cardiovascular risk factors and other comorbidities in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Jul 20. doi: 10.1097/MNH.0000000000000633.
    PubMed    


  33. BALANI S, Perwad F
    Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Jul 20. doi: 10.1097/MNH.0000000000000631.
    PubMed     Abstract available


  34. WALTHER CP, Triozzi JL, Deswal A
    Iron deficiency and iron therapy in heart failure and chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Jul 20. doi: 10.1097/MNH.0000000000000630.
    PubMed     Abstract available


  35. GOONASEKERA MA, Mafham MM, Haynes RJ
    LDL-cholesterol reduction in chronic kidney disease: options beyond statins.
    Curr Opin Nephrol Hypertens. 2020 Jul 20. doi: 10.1097/MNH.0000000000000628.
    PubMed     Abstract available


  36. EDMONSTON DL, Sparks MA
    Therapeutic options for chronic kidney disease-associated pulmonary hypertension.
    Curr Opin Nephrol Hypertens. 2020 Jul 9. doi: 10.1097/MNH.0000000000000624.
    PubMed     Abstract available


  37. COURBON G, Martinez-Calle M, David V
    Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020;29:359-366.
    PubMed     Abstract available


  38. EGSTRAND S, Olgaard K, Lewin E
    Circadian rhythms of mineral metabolism in chronic kidney disease-mineral bone disorder.
    Curr Opin Nephrol Hypertens. 2020;29:367-377.
    PubMed     Abstract available


  39. KURATA Y, Tanaka T, Nangaku M
    Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020;29:414-422.
    PubMed     Abstract available


    May 2020
  40. LIN F
    Molecular regulation and function of FoxO3 in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 May 13. doi: 10.1097/MNH.0000000000000616.
    PubMed     Abstract available


  41. NAIR S, Trivedi M
    Anemia management in dialysis patients: a PIVOT and a new path?
    Curr Opin Nephrol Hypertens. 2020;29:351-355.
    PubMed     Abstract available


    March 2020
  42. CAO J, Singh K
    Integrating risk prediction models into chronic kidney disease care.
    Curr Opin Nephrol Hypertens. 2020 Mar 19. doi: 10.1097/MNH.0000000000000603.
    PubMed     Abstract available


  43. GUERROT D, Humalda JK
    Blood pressure targets in chronic kidney disease: an update on the evidence.
    Curr Opin Nephrol Hypertens. 2020 Mar 9. doi: 10.1097/MNH.0000000000000601.
    PubMed     Abstract available


  44. CURTIS S, Komenda P
    Screening for chronic kidney disease: moving toward more sustainable health care.
    Curr Opin Nephrol Hypertens. 2020 Mar 5. doi: 10.1097/MNH.0000000000000597.
    PubMed     Abstract available


  45. BROGAN M, Astor BC, Melamed ML
    Vitamin D in chronic kidney disease: is there a role outside of PTH control?
    Curr Opin Nephrol Hypertens. 2020;29:243-247.
    PubMed     Abstract available


    February 2020
  46. IMAN Y, Harasemiw O, Tangri N
    Assessing physical function in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2020 Feb 25. doi: 10.1097/MNH.0000000000000594.
    PubMed     Abstract available


    January 2020
  47. BROGAN M, Astor BC, Melamed ML
    Vitamin D in chronic kidney disease: is there a role outside of PTH control?
    Curr Opin Nephrol Hypertens. 2020 Jan 31. doi: 10.1097/MNH.0000000000000591.
    PubMed     Abstract available


  48. URIBARRI J
    Chronic kidney disease and kidney stones.
    Curr Opin Nephrol Hypertens. 2020 Jan 16. doi: 10.1097/MNH.0000000000000582.
    PubMed     Abstract available


  49. KELLER RW JR, Kopple JD, Kalantar-Zadeh K
    Perspiration interventions for conservative management of kidney disease and uremia.
    Curr Opin Nephrol Hypertens. 2020;29:57-63.
    PubMed     Abstract available


    December 2019
  50. KASSEM H, Chatila K
    Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?
    Curr Opin Nephrol Hypertens. 2019 Dec 12. doi: 10.1097/MNH.0000000000000583.
    PubMed     Abstract available


    November 2019
  51. TANTISATTAMO E, Hanna RM, Reddy UG, Ichii H, et al
    Novel options for failing allograft in kidney transplanted patients to avoid or defer dialysis therapy.
    Curr Opin Nephrol Hypertens. 2019 Nov 16. doi: 10.1097/MNH.0000000000000572.
    PubMed     Abstract available


  52. RHEE CM, Nguyen DV, Nyamathi A, Kalantar-Zadeh K, et al
    Conservative vs. preservative management of chronic kidney disease: similarities and distinctions.
    Curr Opin Nephrol Hypertens. 2019 Nov 16. doi: 10.1097/MNH.0000000000000573.
    PubMed     Abstract available


  53. PURI I, Shirazi NM, Yap E, Saggi SJ, et al
    Intestinal dialysis for conservative management of Uremia.
    Curr Opin Nephrol Hypertens. 2019 Nov 12. doi: 10.1097/MNH.0000000000000571.
    PubMed     Abstract available


  54. JOSHI S, Hashmi S, Shah S, Kalantar-Zadeh K, et al
    Plant-based diets for prevention and management of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Nov 12. doi: 10.1097/MNH.0000000000000574.
    PubMed     Abstract available


  55. TANTISATTAMO E, Kalantar-Zadeh K
    Novel therapeutic approaches in chronic kidney disease and uremia management.
    Curr Opin Nephrol Hypertens. 2019 Nov 12. doi: 10.1097/MNH.0000000000000575.
    PubMed    


  56. CUPISTI A, Piccoli GB, Gallieni M
    Charcoal for the management of pruritus and uremic toxins in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Nov 12. doi: 10.1097/MNH.0000000000000567.
    PubMed     Abstract available


  57. HAARHAUS M, Gilham D, Kulikowski E, Magnusson P, et al
    Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Nov 11. doi: 10.1097/MNH.0000000000000570.
    PubMed     Abstract available


  58. PALMER BF, Clegg DJ
    Fluid overload as a therapeutic target for the preservative management of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Nov 9. doi: 10.1097/MNH.0000000000000563.
    PubMed     Abstract available


  59. CLEGG DJ, Palmer BF
    Potassium binding for conservative and preservative management of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Nov 9. doi: 10.1097/MNH.0000000000000564.
    PubMed     Abstract available


  60. MISKULIN DC
    Influenza in dialysis patients: an opportunity to decrease mortality?
    Curr Opin Nephrol Hypertens. 2019;28:607-614.
    PubMed     Abstract available


  61. MCMAHON GM, Singh AK
    Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019;28:600-606.
    PubMed     Abstract available


  62. KODALI L, Turner A
    When are you too old to get a kidney transplants?
    Curr Opin Nephrol Hypertens. 2019;28:593-599.
    PubMed     Abstract available


    September 2019
  63. ALI I, Kalra P
    Risk prediction in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Sep 9. doi: 10.1097/MNH.0000000000000553.
    PubMed     Abstract available


  64. RHEE CM
    Thyroid disease in end-stage renal disease.
    Curr Opin Nephrol Hypertens. 2019 Sep 2. doi: 10.1097/MNH.0000000000000542.
    PubMed     Abstract available


    August 2019
  65. TUNBRIDGE M, Cho Y, Johnson DW
    Urgent-start peritoneal dialysis: is it ready for prime time?
    Curr Opin Nephrol Hypertens. 2019 Aug 20. doi: 10.1097/MNH.0000000000000545.
    PubMed     Abstract available


  66. WELLES CC, Cervantes L
    Hemodialysis care for undocumented immigrants with end-stage renal disease in the United States.
    Curr Opin Nephrol Hypertens. 2019 Aug 8. doi: 10.1097/MNH.0000000000000543.
    PubMed     Abstract available


    July 2019
  67. PICKUP L, Radhakrishnan A, Townend JN, Ferro CJ, et al
    Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?
    Curr Opin Nephrol Hypertens. 2019 Jul 29. doi: 10.1097/MNH.0000000000000535.
    PubMed     Abstract available


    June 2019
  68. CHEN W, Abramowitz MK
    Advances in management of chronic metabolic acidosis in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Jun 19. doi: 10.1097/MNH.0000000000000524.
    PubMed     Abstract available


    May 2019
  69. MARTIN A
    Bone and heart health in chronic kidney disease: role of dentin matrix protein 1.
    Curr Opin Nephrol Hypertens. 2019 May 16. doi: 10.1097/MNH.0000000000000512.
    PubMed     Abstract available


  70. HSU S, Bansal N
    Updates in the management of heart failure for the chronic kidney disease patient.
    Curr Opin Nephrol Hypertens. 2019;28:262-266.
    PubMed     Abstract available


  71. RAMPERSAD C, Dart A
    Widening the lens to childhood: relevance and lifetime risk of kidney failure.
    Curr Opin Nephrol Hypertens. 2019;28:233-237.
    PubMed     Abstract available


    April 2019
  72. VOELKL J, Cejka D, Alesutan I
    An overview of the mechanisms in vascular calcification during chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Apr 9. doi: 10.1097/MNH.0000000000000507.
    PubMed     Abstract available


    March 2019
  73. ZUK A, Bonventre JV
    Recent advances in acute kidney injury and its consequences and impact on chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Mar 28. doi: 10.1097/MNH.0000000000000504.
    PubMed     Abstract available


    February 2019
  74. HA JT, Badve SV, Jun M
    Recent evidence for direct oral anticoagulants in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Feb 14. doi: 10.1097/MNH.0000000000000493.
    PubMed     Abstract available


    January 2019
  75. GORAYA N, Wesson DE
    Clinical evidence that treatment of metabolic acidosis slows the progression of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2019 Jan 23. doi: 10.1097/MNH.0000000000000491.
    PubMed     Abstract available


  76. WALD R, Thorpe KE, Walsh MW
    Leveraging pragmatic clinical trial design to advance phosphate management in end-stage renal disease.
    Curr Opin Nephrol Hypertens. 2019;28:34-39.
    PubMed     Abstract available


    December 2018
  77. ARMSTRONG ME, Thomas CP
    Diagnosis of monogenic chronic kidney diseases.
    Curr Opin Nephrol Hypertens. 2018 Dec 28. doi: 10.1097/MNH.0000000000000486.
    PubMed     Abstract available


  78. GOLDFARB DS
    Controversies in kidney stones and other chronic kidney disease topics.
    Curr Opin Nephrol Hypertens. 2018 Dec 24. doi: 10.1097/MNH.0000000000000485.
    PubMed    


  79. SHAH R, Sparks MA
    Renin-angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go?
    Curr Opin Nephrol Hypertens. 2018 Dec 24. doi: 10.1097/MNH.0000000000000484.
    PubMed     Abstract available


  80. SRIPERUMBUDURI S, Hiremath S
    The case for cautious consumption: NSAIDs in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Dec 5. doi: 10.1097/MNH.0000000000000473.
    PubMed     Abstract available


    November 2018
  81. NG JK, Li PK
    Fluid management and bioimpedance study in peritoneal dialysis.
    Curr Opin Nephrol Hypertens. 2018 Nov 16. doi: 10.1097/MNH.0000000000000466.
    PubMed     Abstract available


  82. FRIEDMAN DJ
    Genes and environment in chronic kidney disease hotspots.
    Curr Opin Nephrol Hypertens. 2018 Nov 16. doi: 10.1097/MNH.0000000000000470.
    PubMed     Abstract available


  83. BURTON JO, Graham-Brown MPM
    Nocturnal hemodialysis: an underutilized modality?
    Curr Opin Nephrol Hypertens. 2018;27:472-477.
    PubMed     Abstract available


  84. PASUPULATI AK, Menon RK
    Growth hormone and chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Nov 1. doi: 10.1097/MNH.0000000000000468.
    PubMed     Abstract available


    October 2018
  85. VALDIVIELSO JM, Jacobs-Cacha C, Soler MJ
    Sex hormones and their influence on chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Oct 12. doi: 10.1097/MNH.0000000000000463.
    PubMed     Abstract available


  86. HANSSEN NMJ, Stehouwer CDA, Schalkwijk CG
    Methylglyoxal stress, the glyoxalase system, and diabetic chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Oct 12. doi: 10.1097/MNH.0000000000000465.
    PubMed     Abstract available


    September 2018
  87. BEAUBIEN-SOULIGNY W, Bouchard J, Denault A
    Point-of-care ultrasound in end-stage kidney disease: beyond lung ultrasound.
    Curr Opin Nephrol Hypertens. 2018 Sep 3. doi: 10.1097/MNH.0000000000000453.
    PubMed     Abstract available


  88. HASEGAWA S, Tanaka T, Nangaku M
    Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018;27:331-338.
    PubMed     Abstract available


    August 2018
  89. KALIM S
    Protein carbamylation in end stage renal disease: is there a mortality effect?
    Curr Opin Nephrol Hypertens. 2018 Aug 24. doi: 10.1097/MNH.0000000000000454.
    PubMed     Abstract available


  90. NIANG A, Iyengar A, Luyckx VA
    Hemodialysis versus peritoneal dialysis in resource-limited settings.
    Curr Opin Nephrol Hypertens. 2018 Aug 24. doi: 10.1097/MNH.0000000000000455.
    PubMed     Abstract available


  91. PONCE D, Brabo AM, Balbi AL
    Urgent start peritoneal dialysis.
    Curr Opin Nephrol Hypertens. 2018 Aug 22. doi: 10.1097/MNH.0000000000000451.
    PubMed     Abstract available


    July 2018
  92. TABINOR M, Davies SJ
    The use of bioimpedance spectroscopy to guide fluid management in patients receiving dialysis.
    Curr Opin Nephrol Hypertens. 2018 Jul 30. doi: 10.1097/MNH.0000000000000445.
    PubMed     Abstract available


  93. KALRA PA, Burlacu A, Ferro CJ, Covic A, et al
    Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?
    Curr Opin Nephrol Hypertens. 2018 Jul 16. doi: 10.1097/MNH.0000000000000443.
    PubMed     Abstract available


  94. ERBEN RG
    alpha-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent.
    Curr Opin Nephrol Hypertens. 2018;27:229-235.
    PubMed     Abstract available


    June 2018
  95. ALI S, Dave N, Navaneethan SD
    Emerging therapeutic options for management of anaemia in with patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Jun 22. doi: 10.1097/MNH.0000000000000434.
    PubMed    


  96. MACDOUGALL IC
    Iron therapy for managing anaemia in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Jun 13. doi: 10.1097/MNH.0000000000000436.
    PubMed     Abstract available


    May 2018
  97. JELKMANN W
    Activin receptor ligand traps in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 May 29. doi: 10.1097/MNH.0000000000000433.
    PubMed     Abstract available


  98. DUBIN RF
    Application of echocardiographic data in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 May 16. doi: 10.1097/MNH.0000000000000419.
    PubMed     Abstract available


  99. GUPTA N, Wish JB
    Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 May 4. doi: 10.1097/MNH.0000000000000430.
    PubMed     Abstract available


  100. DEKKER MJE, Kooman JP
    Fluid status assessment in hemodialysis patients and the association with outcome: review of recent literature.
    Curr Opin Nephrol Hypertens. 2018;27:188-193.
    PubMed     Abstract available


    April 2018
  101. STRAUSSER SA, Nakano D, Souma T
    Acute kidney injury to chronic kidney disease transition: insufficient cellular stress response.
    Curr Opin Nephrol Hypertens. 2018 Apr 26. doi: 10.1097/MNH.0000000000000424.
    PubMed     Abstract available


  102. MOE SM
    Rationale to reduce calcium intake in adult patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Apr 26. doi: 10.1097/MNH.0000000000000416.
    PubMed     Abstract available


  103. SCIALLA JJ
    Evidence basis for integrated management of mineral metabolism in patients with end-stage renal disease.
    Curr Opin Nephrol Hypertens. 2018 Apr 6. doi: 10.1097/MNH.0000000000000417.
    PubMed     Abstract available


    March 2018
  104. STELLER WAGNER MARTINS C, Jorgetti V, Moyses RMA
    Time to rethink the use of bone biopsy to prevent fractures in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Mar 31. doi: 10.1097/MNH.0000000000000418.
    PubMed     Abstract available


  105. ASHLEY J, Sood MM
    Novel oral anticoagulants in chronic kidney disease: ready for prime time?
    Curr Opin Nephrol Hypertens. 2018 Mar 22. doi: 10.1097/MNH.0000000000000410.
    PubMed     Abstract available


  106. CONNELLY K, Collister D, Tangri N
    Fracture risk and treatment in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2018 Mar 15. doi: 10.1097/MNH.0000000000000411.
    PubMed     Abstract available


    February 2018
  107. LI T, Xie Y, Al-Aly Z
    The association of proton pump inhibitors and chronic kidney disease: cause or confounding?
    Curr Opin Nephrol Hypertens. 2018 Feb 9. doi: 10.1097/MNH.0000000000000406.
    PubMed     Abstract available


    January 2018
  108. HAAS M
    Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts.
    Curr Opin Nephrol Hypertens. 2018 Jan 2. doi: 10.1097/MNH.0000000000000398.
    PubMed     Abstract available


    December 2017
  109. RAO M, Jaber BL, Balakrishnan VS
    Chronic kidney disease and acquired mitochondrial myopathy.
    Curr Opin Nephrol Hypertens. 2017 Dec 20. doi: 10.1097/MNH.0000000000000393.
    PubMed     Abstract available


    November 2017
  110. KRAUT JA, Madias NE
    Retarding progression of chronic kidney disease: use of modalities that counter acid retention.
    Curr Opin Nephrol Hypertens. 2017 Nov 14. doi: 10.1097/MNH.0000000000000386.
    PubMed     Abstract available


  111. SCHMIDT RJ
    Incorporating supportive care into the hemodialysis unit.
    Curr Opin Nephrol Hypertens. 2017;26:530-536.
    PubMed     Abstract available


    October 2017
  112. WALTHER CP, Chandra A, Navaneethan SD
    Blood pressure parameters and morbid and mortal outcomes in nondialysis-dependent chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2017 Oct 16. doi: 10.1097/MNH.0000000000000375.
    PubMed     Abstract available


    September 2017
  113. GOLPER TA
    Incremental dialysis: review of recent literature.
    Curr Opin Nephrol Hypertens. 2017 Sep 11. doi: 10.1097/MNH.0000000000000362.
    PubMed     Abstract available


  114. SY J, Johansen KL
    The impact of frailty on outcomes in dialysis.
    Curr Opin Nephrol Hypertens. 2017 Sep 9. doi: 10.1097/MNH.0000000000000364.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Renal Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: